| 8AP Stock | | | EUR 50.50 0.50 0.98% |
Founder
Dr. Lewis C. Cantley, Ph.D., is Director of Agios Pharmaceuticals, Inc. Dr. Cantley has served as a director of the Cancer Center at Weill Cornell Medical College and New YorkPresbyterian Hospital since October 2012. Prior to that, from 1992 to 2012, Dr. Cantley was a professor of systems biology at Harvard Medical School and chief of the division of Signal Transduction at Beth Israel Deaconess Medical Center, a major teaching hospital of Harvard Medical School in Boston. From 2007 to 2012, Dr. Cantley also served as director of the Cancer Center at Beth Israel Deaconess Medical Center. Dr. Cantley is a member of the American Academy of Arts and Sciences and the National Academy of Sciences, and serves on the editorial boards of the journals Cell and the Journal of Cell Biology. He currently serves on the board of directors of the American Association of Cancer Research and Hope Foundation for Cancer Research, nonprofit organizations that promote cancer research. Dr. Cantley is the recipient of the 2005 Pezcoller FoundationAmerican Association for Cancer Research International Award for Cancer Research, for his leadership in the field of signal transduction, including the discovery of the phosphatidylinositol3kinase signaling pathway since 2007.
| Age | 74 |
| Tenure | 17 years |
| Professional Marks | Ph.D |
| Phone | 617 649 8600 |
| Web | https://www.agios.com |
Cantley received his B.S. in chemistry from West Virginia Wesleyan College, and obtained a Ph.D. in biophysical chemistry from Cornell University.
Agios Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
(0.1813) % which means that it has lost $0.1813 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.1979) %, meaning that it generated substantial loss on money invested by shareholders. Agios Pharmaceuticals' management efficiency ratios could be used to measure how well Agios Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Agios Pharmaceuticals has accumulated 116.47
M in total debt with debt to equity ratio
(D/E) of 21.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Agios Pharmaceuticals has a current ratio of 5.84, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Agios Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Agios Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Agios Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Agios to invest in growth at high rates of return. When we think about Agios Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. AGIOS PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 482 people. Agios Pharmaceuticals (8AP) is traded on Frankfurt Exchange in Germany and employs 25 people.
Management Performance
Agios Pharmaceuticals Leadership Team
Elected by the shareholders, the Agios Pharmaceuticals' board of directors comprises two types of representatives: Agios Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Agios. The board's role is to monitor Agios Pharmaceuticals' management team and ensure that shareholders' interests are well served. Agios Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Agios Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| DSc FRSC, CoFounder Board | |
| Dr DACVP, Consultant | |
| Sarah MD, Chief RD | |
| T Washburn, Principal Officer | |
| Craig MD, CoFounder Board | |
| Cecilia Jones, Chief Officer | |
| Richa Poddar, Chief Officer | |
| ShinSan Su, CoFounder Board | |
| Lewis Cantley, CoFounder Board | |
| Brian MBA, CEO Director | |
Agios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Agios Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Agios Stock
Agios Pharmaceuticals financial ratios help investors to determine whether Agios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Agios with respect to the benefits of owning Agios Pharmaceuticals security.